Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II photodynamic therapy with talaporfin sodium and diode laser for cervical intraepithelial neoplasia
jRCT2041190087Phase 2Completed
- Sponsor
- Meiji Seika Pharma Co., Ltd.
- Start
- Mar 2020
- Modality
- Light/Condition-Responsive Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of talaporfin sodium in cervical intraepithelial neoplasia (CIN), sponsored by Meiji Seika Pharma Co., Ltd. Primary endpoint: Complete response. Started Mar 2020; status: completed.
02
Drugs
talaporfin sodium
03
Conditions
cervical intraepithelial neoplasia (CIN)
Beyond the preview
Go deeper on jRCT2041190087.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2041190087.